Panagora Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Panagora Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-42,001	Closed	-$2.86M	–	1548
2022 Q3	$2.86M	Sell	42,001 -61,563	-59%	-$3.4M	0.02%	508
2022 Q2	$3.31M	Buy	103,564 +8,190	+9%	+$240K	0.02%	489
2022 Q1	$3.3M	Buy	95,374 +5,086	+6%	+$152K	0.02%	525
2021 Q4	$2.64M	Buy	+90,288	New	+$2.8M	0.01%	560
2021 Q3	–	Sell	-2,790	Closed	-$98K	–	2708
2021 Q2	$98K	Sell	2,790 -201	-7%	-$7.85K	﹤0.01%	1908
2021 Q1	$122K	Buy	2,991 +2,628	+724%	+$121K	﹤0.01%	1892
2020 Q4	$16K	Sell	363 -24	-6%	-$1.18K	﹤0.01%	2232
2020 Q3	$21K	Buy	387 +50	+15%	+$3.18K	﹤0.01%	2200
2020 Q2	$21K	Buy	+337	New	+$23.1K	﹤0.01%	2136
2017 Q3	–	Sell	-714	Closed	-$20K	–	2556
2017 Q2	$20K	Buy	+714	New	+$21.2K	﹤0.01%	2276
2016 Q1	–	Sell	-5,908	Closed	-$191K	–	2359
2015 Q4	$191K	Buy	+5,908	New	+$256K	﹤0.01%	1604

Other funds holding GBT

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Panagora Asset Management's GBT Position: Q4 2022 in Review

Panagora Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 42,001 shares — an estimated $2.86M sold.

Panagora Asset Management first reported a position in GBT in Q4 2015 and held it in 11 quarters. The position peaked at $3.31M in Q2 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Panagora Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Panagora Asset Management sold 42,001 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2.86M.
Panagora Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2015 and held it in 11 quarters.
Panagora Asset Management's Global Blood Therapeutics, Inc. position peaked at $3.31M in Q2 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Panagora Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.